Knowledge HQ

This study compares Solupore and electroporation for manufacturing multi-edited CAR-T cells. Solupore-transfected cells showed higher viability, TSCM retention, and in vivo efficacy. 24-well G-Rex were used to assess cell proliferation and cytokine production, supporting metabolic health analysis.

This study describes the MC3 protocol for lung TIL manufacturing, which simplifies the process by using G-Rex for both preREP and REP phases and replacing feeder cells with CD3/CD28 nanobeads. The method reduced culture time and costs while producing TILs with superior cytotoxicity against tumor organoids.

This poster evaluates cGMP T cell expansion protocols using ImmunoCult reagents across G-Rex (6M plate and 50M bottle), Xuri, and PBS-MINI bioreactors. G-Rex produced high cell densities and yields of functional T cells, including central memory subsets, suitable for clinical manufacturing.

This abstract presents SENTI-202, a logic-gated CAR-NK therapy for AML. The EMCN inhibitory CAR protects healthy HSCs from off-tumor toxicity. R&D scale CAR-NK cell manufacturing utilized 1L G-Rex for expansion, achieving high cell numbers and viability while maintaining logic gate function.

The authors developed 'enGager', a Cas9 fusion system that tethers cssDNA donors to enhance non-viral targeted integration. Used to engineer CD19/CD22 dual CAR-T cells. Post-electroporation, T cells were transferred to G-Rex 24-well plates for expansion, achieving high knock-in efficiency and cell viability.

This review analyzes automated cell therapy manufacturing systems. It highlights the G-Rex as a key technology for simplified static expansion compared to flasks. It notes that the Multiply Labs robotic cluster integrates G-Rex 100M for automated, parallel T cell expansion.

This study demonstrates that tuning the affinity of the TAC receptor's TCR-binding domain improves in vivo anti-tumor potency. CLDN18.2-TAC T cells were engineered and expanded using the G-Rex system. Lower affinity UCHT1 variants led to superior functional outcomes in solid tumor models.

This protocol describes the isolation and feeder-cell-based expansion of NK cells. To demonstrate clinical scalability, the method was tested on GMP-grade G-Rex 100M platforms, achieving clinically relevant numbers of highly pure and functional NK cells suitable for adoptive therapy.

This study introduces RESET, a two-component receptor system engaging the endogenous TCR with drug-regulated control. RESET-T cells exhibited superior sensitivity and potency compared to CARs. G-Rex vessels were used for the culture and expansion of the engineered T cells during the study.

This study establishes an optimized platform for expanding and genetically modifying NK cells. Using KBM581 medium with serum replacement in 24-well G-Rex plates, the authors achieved over 5000-fold expansion in 14 days. The protocol supports efficient viral transduction and gene editing of NK cells.

This study demonstrates a semi-automated workflow for non-viral CAR T-cell production using digitally connected instruments. T cells were isolated, activated, and then cultured in G-Rex 100 and G-Rex 100M. The process yielded high-quality CAR T cells with reduced manual touchpoints and variability.

The authors developed a GMP-feasible protocol for expanding TILs from sarcoma without anti-CD137 agonist, using CD3/CD28 beads instead. The rapid expansion phase (REP) utilized G-Rex 10M, which achieved a 2- to 3-fold higher expansion compared to T-75 flasks, boosting clinical feasibility.